S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.69 (-2.00%)
AAPL   171.99 (-1.24%)
MSFT   286.19 (-1.37%)
META   168.11 (-3.75%)
GOOGL   117.16 (-2.50%)
AMZN   138.23 (-2.86%)
TSLA   883.54 (-2.76%)
NVDA   178.22 (-5.07%)
NIO   19.06 (-4.27%)
BABA   89.62 (-1.23%)
AMD   94.97 (-5.45%)
T   18.41 (-0.11%)
MU   60.53 (-3.89%)
CGC   3.81 (+0.00%)
F   15.82 (-2.04%)
GE   77.55 (-2.10%)
DIS   120.14 (-2.06%)
AMC   17.96 (-6.89%)
PYPL   96.87 (-2.99%)
PFE   49.39 (+1.67%)
NFLX   238.05 (-2.90%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.69 (-2.00%)
AAPL   171.99 (-1.24%)
MSFT   286.19 (-1.37%)
META   168.11 (-3.75%)
GOOGL   117.16 (-2.50%)
AMZN   138.23 (-2.86%)
TSLA   883.54 (-2.76%)
NVDA   178.22 (-5.07%)
NIO   19.06 (-4.27%)
BABA   89.62 (-1.23%)
AMD   94.97 (-5.45%)
T   18.41 (-0.11%)
MU   60.53 (-3.89%)
CGC   3.81 (+0.00%)
F   15.82 (-2.04%)
GE   77.55 (-2.10%)
DIS   120.14 (-2.06%)
AMC   17.96 (-6.89%)
PYPL   96.87 (-2.99%)
PFE   49.39 (+1.67%)
NFLX   238.05 (-2.90%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.69 (-2.00%)
AAPL   171.99 (-1.24%)
MSFT   286.19 (-1.37%)
META   168.11 (-3.75%)
GOOGL   117.16 (-2.50%)
AMZN   138.23 (-2.86%)
TSLA   883.54 (-2.76%)
NVDA   178.22 (-5.07%)
NIO   19.06 (-4.27%)
BABA   89.62 (-1.23%)
AMD   94.97 (-5.45%)
T   18.41 (-0.11%)
MU   60.53 (-3.89%)
CGC   3.81 (+0.00%)
F   15.82 (-2.04%)
GE   77.55 (-2.10%)
DIS   120.14 (-2.06%)
AMC   17.96 (-6.89%)
PYPL   96.87 (-2.99%)
PFE   49.39 (+1.67%)
NFLX   238.05 (-2.90%)
S&P 500   4,234.92 (-1.14%)
DOW   33,773.07 (-0.66%)
QQQ   322.69 (-2.00%)
AAPL   171.99 (-1.24%)
MSFT   286.19 (-1.37%)
META   168.11 (-3.75%)
GOOGL   117.16 (-2.50%)
AMZN   138.23 (-2.86%)
TSLA   883.54 (-2.76%)
NVDA   178.22 (-5.07%)
NIO   19.06 (-4.27%)
BABA   89.62 (-1.23%)
AMD   94.97 (-5.45%)
T   18.41 (-0.11%)
MU   60.53 (-3.89%)
CGC   3.81 (+0.00%)
F   15.82 (-2.04%)
GE   77.55 (-2.10%)
DIS   120.14 (-2.06%)
AMC   17.96 (-6.89%)
PYPL   96.87 (-2.99%)
PFE   49.39 (+1.67%)
NFLX   238.05 (-2.90%)
LON:HIK

Hikma Pharmaceuticals - HIK Share Forecast, Price & News

GBX 1,439.41
-1.59 (-0.11%)
(As of 08/19/2022 05:06 PM ET)
Add
Compare
Today's Range
1,424
1,448
50-Day Range
1,440.99
1,762
52-Week Range
1,424
2,625
Volume
410,230 shs
Average Volume
652,605 shs
Market Capitalization
£3.17 billion
P/E Ratio
1,160.82
Dividend Yield
2.91%
Price Target
GBX 2,268.33

Hikma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
57.6% Upside
GBX 2,268.33 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.13mentions of Hikma Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

HIK stock logo

About Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Morgan Stanley reiterated an "equal weight" rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, May 11th. Barclays downgraded Hikma Pharmaceuticals to an "equal weight" rating and cut their target price for the company from GBX 2,250 ($27.19) to GBX 1,750 ($21.15) in a research report on Friday, August 5th. Finally, JPMorgan Chase & Co. cut their target price on Hikma Pharmaceuticals from GBX 1,900 ($22.96) to GBX 1,760 ($21.27) and set a "neutral" rating for the company in a research report on Thursday, August 11th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of "Hold" and an average target price of GBX 2,268.33 ($27.41).

Hikma Pharmaceuticals Price Performance

Shares of HIK Stock opened at GBX 1,445 ($17.46) on Friday. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt-to-equity ratio of 70.79. Hikma Pharmaceuticals has a twelve month low of GBX 1,424 ($17.21) and a twelve month high of GBX 2,625 ($31.72). The company has a market cap of £3.18 billion and a P/E ratio of 1,162.10. The business has a fifty day simple moving average of GBX 1,628.17 and a 200 day simple moving average of GBX 1,821.03.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, September 19th. Investors of record on Thursday, August 18th will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Thursday, August 18th. This represents a dividend yield of 0.89%. Hikma Pharmaceuticals's dividend payout ratio is currently 41.81%.

Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Stock News Headlines

Mallinckrodt plc Provides Update on Executive Committee
Is the Hikma Pharmaceuticals share price too low?
Drugmaker Hikma CEO Olafsson to step down
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Company Calendar

Ex-Dividend for 9/19 Dividend
8/18/2022
Today
8/19/2022
Dividend Payable
9/19/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
8,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 2,268.33
High Stock Price Forecast
GBX 2,880
Low Stock Price Forecast
GBX 1,750
Forecasted Upside/Downside
+57.6%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.55 billion
Cash Flow
GBX 178.30 per share
Book Value
GBX 988.60 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.17 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 65)
    Exec. Chairman & CEO
    Comp: $2.71M
  • Mr. Mazen Samih Taleb Darwazah (Age 64)
    Exec. Vice Chairman & Pres of MENA
    Comp: $2.11M
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 50)
    Chief Financial Officer
  • Dr. Shahin Fesharaki
    Chief Scientific Officer
  • Mr. Hussein Arkhagha
    Company Sec. & Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 57)
    CPA, Exec. VP of Corp. Devel. and M&A
  • Ms. Susan Ringdal
    Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi
    Exec. VP of Organisational Devel.
  • Mr. Riad Mishlawi
    Pres of Injectables
  • Mr. Brian Hoffmann
    Pres of Generics













HIK Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIK, but not buy additional shares or sell existing shares.
View HIK analyst ratings
or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price forecast for 2022?

6 analysts have issued 1-year price targets for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,750 to GBX 2,880. On average, they predict the company's stock price to reach GBX 2,268.33 in the next twelve months. This suggests a possible upside of 58.3% from the stock's current price.
View analysts price targets for HIK
or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2022?

Hikma Pharmaceuticals' stock was trading at GBX 2,219 at the beginning of the year. Since then, HIK shares have decreased by 35.4% and is now trading at GBX 1,432.50.
View the best growth stocks for 2022 here
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, August 4th. Shareholders of record on Thursday, August 18th will be given a dividend of GBX 0.19 per share on Monday, September 19th. This represents a yield of 0.89%. The ex-dividend date of this dividend is Thursday, August 18th. The official announcement can be accessed at this link.
Read our dividend analysis for HIK
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 0.52 per share and currently has a dividend yield of 2.91%. The dividend payout ratio is 41.81%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,432.50.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.15 billion and generates £2.55 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.

This page (LON:HIK) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.